MAXCYTE Business Summary

MaxCyte, Inc. (MXCT) is a premier life-sciences tools provider that generates revenue through a diversified model of instrument sales, recurring consumables, and high-margin Strategic Platform Licenses (SPLs). The company’s core business segment centers on its proprietary ExPERT™ flow electroporation platform—including the ATx, STx, GTx, VLx, and the high-throughput DTx systems—which enables the non-viral engineering of diverse cell types. Revenue streams are comprised of upfront equipment sales, single-use processing assembly fees, and long-term licensing agreements that yield clinical milestones and post-approval royalties. Following the acquisition of SeQure Dx, the company also provides specialized gene-editing characterization and risk assessment services. MaxCyte competes with global life-science giants such as Lonza Group AG, Thermo Fisher Scientific Inc., Sartorius AG, and 10x Genomics. It maintains a unique market position as a specialized technology partner whose platform is integrated into the regulatory filings of dozens of clinical-stage cell therapy programs, including the first FDA-approved CRISPR-edited therapy. Founded in 1998 by Douglas Doerfler, who led the company through its Nasdaq IPO before retiring in 2024, MaxCyte is currently headed by President and CEO Maher Masoud. Masoud, who previously served as the company’s Executive VP and General Counsel, brings over 25 years of biopharmaceutical experience, including key roles at Human Genome Sciences and Wellstat. The executive team was further bolstered in March 2026 by the appointment of Chief Financial Officer Parmeet Ahuja, a former finance leader at Agilent Technologies with extensive expertise in global operations and investor relations. The company is governed by a board chaired by Richard Douglas, PhD (formerly of Genzyme), and includes notable directors such as Patrick Balthrop, Sr. (former Luminex CEO) and Stanley Erck (former Novavax CEO). MaxCyte is backed by a robust base of institutional investors and recently signaled confidence in its long-term strategy by authorizing a $10 million share repurchase program in May 2026.